World-leading capabilities in multiplexable gene editing
Join Our Team
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Newsroom
Press Releases
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 20222022/04/08
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
1 / 3Press Releases
Qihan Biotech Raises Additional USD 67 Million in Series A++ Financing. Funds to Advance Pipeline of Novel Cell and Organ Therapies2021/03/28
Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.
1 / 3Press Releases
Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering2020/09/20
In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).
1 / 3
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311231
TEL: 0571-83500380
FAX: 0571-83500370